A new group called the European Life Sciences Coalition has started in Brussels. Its goal is to encourage more investment in health and biotech startups in Europe. This group includes leading investment firms, research centers, and other important players in the field. Together, they manage over €24 billion and have helped more than 1,400 companies. They want to share their practical insights on how to improve funding and growth for these companies. The coalition is responding to concerns that Europe is struggling to keep and grow its health and biotech innovations, despite having strong scientific foundations. Some of the challenges they highlight include not using private savings well, having fragmented capital markets, a decline in specialized investment firms, and slow, inconsistent regulations. These issues make it hard for promising companies to get the money they need and often push them to seek funding outside the EU. The launch of this coalition is timely as European policymakers are focusing on becoming more self-sufficient, integrating capital markets, and improving competitiveness. The health and biotech sector supports around 29 million jobs in the EU, is crucial for public health and economic resilience, and plays a key role in developing and manufacturing life-saving medicines. The coalition warns that without decisive action, Europe risks losing its position in the health and biotech investment field, which could affect long-term growth, innovation, and patient access. Currently, European life sciences investment funds make up just 7% of the global market, compared to 63% in the United States and 14% in China. Additionally, 66 out of 67 EU biotech companies that went public in the past six years did so outside the EU. The coalition aims to reverse these trends by advocating for better mobilization of startup and growth capital and a more integrated, efficient investment environment. They emphasize that they are not asking for financial aid but for a fundamental shift in how European capital is used. They plan to work with policymakers and Invest Europe to ensure that the continent can finance, grow, and retain its health and biotech innovations.